Drug Profile
Follitropin alfa biosimilar - AbbVie
Alternative Names: Follicle stimulating hormone biosimilar - Actavis/Itero Biopharmaceuticals; rFSH biosimilar - Actavis/Itero BiopharmaceuticalsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Itero Biopharmaceuticals
- Developer AbbVie
- Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
- Mechanism of Action Hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Female infertility
Most Recent Events
- 02 Mar 2021 Discontinued - Phase-III for Female infertility in USA, Spain, Belgium, Austria and United Kingdom (SC) (Abbvie pipeline, March 2021)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 18 Feb 2019 No recent reports of development identified for Phase-III development in Female infertility in United Kingdom (SC)